$LFWD

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of President and Chief Executive Officer Effective August 31, 2026, Mr. Mark Grant will depart from his positions

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. Appointment of Directors On August 14, 2026, the Board of Directors (the “Board”) of Lifeward Ltd. (the “Company”) appointed

Lifeward Ltd. (Nasdaq: LFWD) reported Q2 2026 revenue up 16% to $6.6 million from $5.7 million a year earlier, driven by ReWalk sales rising 13% to $2.5 million and AlterG products and services up 25% to $4.1 million. Gross margin was 41%. Net loss was $11.5 million ($4.12/share). The company said it raised about $5.6 million in July financing and launched a pilot with Ottobock Care.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation pl

Lifeward Ltd. (NASDAQ: LFWD) said it will release its Q2 2026 financial results on Friday, Aug. 14, via a press release and an SEC quarterly report filed before 9:30 a.m. ET. The company highlighted its neurorehabilitation products and its Protein Oral Delivery platform, including ORMD-0801 oral insulin.

Lifeward Ltd. (Nasdaq: LFWD) said it entered a securities purchase agreement for strategic financing with institutional investors. The initial July 6 closing provides about $5.6M in senior secured convertible notes and warrants, with up to another $5.6M tied to milestones: 150% ReWalk unit sales growth or shares at/above $13.80 for 10 days.

Lifeward Ltd. (LFWD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 7 exhibit_10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of June 30, 2026, among Lifeward Ltd., a company organized under the laws of the State of Israel (the “ Company ”), each purchase

Lifeward Ltd. (NASDAQ:LFWD) shares rose 5.6% after hours after the company said it raised $5.6M via senior secured convertible notes and warrants, with another $5.6M available upon milestones: a 150% increase in ReWalk unit sales or shares trading at/above $13.80 for 10 straight days. Lifeward links the financing to a strategic framework with Oramed (NASDAQ:ORMP).

Oramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.

Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss